Evidence map›Paper›PMID 34938991›Full record

ArticleMaterials today. Bio2022

Functional resveratrol-biodegradable manganese doped silica nanoparticles for the spinal cord injury treatment.

Xue Jiang, Xiaoyao Liu, Qi Yu, Wenwen Shen, Xifan Mei, He Tian, Chao Wu

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 3 pooled it
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 44 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Nanocarrier-mediated drug delivery systems for spinal cord injury treatment.Frontiers in bioengineering and biotechnology · 2025
    Review
  14. Article
  15. Article
  16. Nanotherapeutics for Alleviating Anesthesia-Associated Complications.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024
    Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Xue JiangPharmacy School, Jinzhou Medical University, Jinzhou, Liaoning, 121001, China.
Xiaoyao LiuPharmacy School, Jinzhou Medical University, Jinzhou, Liaoning, 121001, China.
Qi YuPharmacy School, Jinzhou Medical University, Jinzhou, Liaoning, 121001, China.
Wenwen ShenPharmacy School, Jinzhou Medical University, Jinzhou, Liaoning, 121001, China.
Xifan MeiDepartment of Orthopedics, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning, 121001, China.
He TianDepartment of Histology and Embryology, Jinzhou Medical University, Jinzhou, Liaoning, 121001, China.
Chao WuPharmacy School, Jinzhou Medical University, Jinzhou, Liaoning, 121001, China.
Jinzhou Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Spinal cord injury (SCI) causes secondary injury, accompanied by pathological changes such as oxidative stress, inflammation and neuronal apoptosis. This leads to permanent disabilities such as paralysis and loss of movement or sensation. Due to the ineffectiveness of drugs passing through the blood spinal cord barrier (BSCB), there is currently no effective treatment for SCI. The aim of this experiment was to design plasma complex component functionalized manganese-doped silica nanoparticles (PMMSN) with a redox response as a targeted drug carrier for resveratrol (RES), which effectively transports insoluble drugs to cross the BSCB. RES was adsorbed into PMMSN with a particle size of approximately 110 ​nm by the adsorption method, and the drug loading reached 32.61 ​± ​3.38%. The RES release results for the loaded sample (PMMSN-RES) showed that the PMMSN-RES exhibited a release slowly effect. In vitro and vivo experiments demonstrated that PMMSN-RES decreased reactive oxygen species (ROS) and malondialdehyde (MDA), increased superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) activities, reduced the expression of inflammatory (TNF-α, IL-1β and IL-6) and apoptotic cytokines (cleaved caspase-3) in spinal cord tissue after SCI. In summary, PMMSN-RES may be a potential pharmaceutical preparation for the treatment of SCI by reducing neuronal apoptosis and inhibiting inflammation caused by reducing oxidative stress to promote the recovery of mouse motor function.

Indexed as

BSCB, blood spinal cord barrierGSH-Px, glutathione peroxidaseH2O2, hydrogen peroxideManganese-doped silica nanoparticlesMDA, malondialdehydeMMSN, manganese-doped mesoporous silica nanoparticlesMnO2, manganese dioxideNeuronal apoptosisOxidative stressPMMSN, plasma complex component functionalized manganese-doped silica nanoparticlesRedox responseRES, resveratrolResveratrolROS, reactive oxygen speciesSCI, spinal cord injurySOD, increased superoxide dismutaseSpinal cord injury

Identifiers

PMID34938991
PMCPMC8661701
OpenAlexW4200126362

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.